First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71

(2016) Tony Taldone et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

The epichaperome is an integrated chaperome network that facilitates tumour survival

(2016) Anna Rodina et al.   NATURE

Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis

(2015) Joanne Ngeow et al.   JOURNAL OF CLINICAL ONCOLOGY

PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction

(2015) Matthew Trendowski   PHARMACOLOGICAL RESEARCH

A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways

(2014) Mikko Taipale et al.   CELL

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

(2014) Komal Jhaveri et al.   Clinical Breast Cancer

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

(2014) Komal Jhaveri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Selective targeting of the stress chaperome as a therapeutic strategy

(2014) Tony Taldone et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2

(2013) Cindy Gallerne et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies

(2013) U. Nayar et al.   BLOOD

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

(2013) Jonathan W Goldman et al.   BMC CANCER

Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71

(2013) TATSUYA SEGAWA et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

(2013) Zhuling Qu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

(2013) Jim Sang et al.   Cancer Discovery

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones

(2011) David Siegel et al.   BIOCHEMICAL PHARMACOLOGY

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

(2011) Kamalika Moulick et al.   Nature Chemical Biology

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

(2011) William K. Oh et al.   UROLOGY

Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs

(2010) Yuval Samuni et al.   FREE RADICAL BIOLOGY AND MEDICINE

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

(2010) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting HSP90 for cancer therapy

(2009) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside

(2009) Saad Usmani et al.   CURRENT MOLECULAR MEDICINE

Purine-Scaffold Hsp90 Inhibitors

(2009) Tony Taldone et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Update on Hsp90 Inhibitors in Clinical Trial

(2009) Y. Kim et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma

(2009) Marco Breinig et al.   HEPATOLOGY

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas

(2009) Leandro C Cerchietti et al.   NATURE MEDICINE

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

(2009) E. Caldas-Lopes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

(2008) Tzu-Yin Lin et al.   EXPERIMENTAL HEMATOLOGY